Webinar on October 19 @ 11a-12p Eastern
Supply chain leaders in life sciences companies operate in a highly uncertain environment. Commercial and regulatory uncertainty is now compounded by the risk of supply disruptions and geopolitical barriers. For companies managing the complexity of multiple products, regions and supply chains, the ability to analyze and evaluate scenarios before they turn into emergencies is critical. It allows for understanding options and developing contingency plans. Taking uncertainty into account in the supply chain planning process and S&OP improves manufacturing and supply decision-making in a way that is easily adaptable as the portfolio grows.
Join us for a webinar on dealing effectively with risk and uncertainty in your planning process and S&OP.
Attendees will gain:
- An understanding of the important elements of planning for uncertainty
- How to integrate risks and uncertainties into S&OP
- How the process will need to evolve over time to maintain success
You will also hear directly from an industry leading company who has successfully managed these risks in their planning process.
Speakers
Thierry Bilbault
SVP of Manufacturing & Pharmaceutical Development, Akebia Therapeutics
Thierry Bilbault is a global pharmaceutical leader with over 20 years of experience in the evaluation, development, transfer, and commercialization of innovative drugs (Rx/OTC/switches), medical devices (Type II and III) and cosmetic products. A technical expert in technology screening, drug delivery systems evaluation, formulation and packaging optimization, and process scale-up and validation, as well as internal and outsourced technology transfer of semisolids, transdermal, film/patches, liquid and solid (IR, MR, SR) dosage forms, he is an effective director of complex organizations with a strong background in leading global technology transfer and development teams, managing global programs, building organizations, and developing technology and product strategies. Prior to Akebia, he served as the head of Technical Operations for Sunovion Pharmaceuticals and as Chief Scientific Officer and EVP of CMC for Cynapsus Therapeutics, as well as leadership roles with Galderma, Novartis, and Pfizer.
Jeremy Friedler
Director of Biotechnology & Pharmaceutical Operations, Converge Consulting
Jeremy Friedler is a biotechnology and pharmaceutical consultant with 15+ years of strategy and operations experience in the life sciences industry. Jeremy brings knowledge and expertise in clinical and commercial supply chain management, strategic and long-range operations planning, supplier/CMO management, small and large molecule manufacturing/CMC and cGMP quality. Through his work with emerging and established biopharma companies he has a unique and well-rounded perspective for addressing a range of challenges these companies face. Prior to Converge, Jeremy was a senior manager in the Pharmaceutical & Life Sciences practice at PricewaterhouseCoopers, providing operations advisory services for corporate strategic initiatives for mid-sized to global biopharmaceutical companies. In earlier roles, he honed his operations planning skills in the Strategy & Operations practice of Maxiom Consulting Group. Jeremy began his career in manufacturing, CMC, clinical supply chain, and commercial launch planning at ARIAD Pharmaceuticals and Alnylam Pharmaceuticals.
Sean Carroll
Supply Chain Consultant, Converge Consulting
Sean Carroll is a supply chain consultant delivering planning solutions for emerging biopharma companies. Sean has a track record of surpassing objectives through strong project leadership, client alignment, relationship-building, and analytical modeling. He collaborates with biopharma clients to design and run S&OP and supply planning business operations, including having provided interim leadership. Sean has created long-range manufacturing plans to alleviate capacity constraints and developed solutions for both product shortages and short-dated inventory. Before Converge, Sean was the senior director of strategic sourcing for Gilead Sciences and supply chain director for KLA Corporation.